MedLife becomes the first private healthcare company in Romania to exceed half a billion euros in turnover in 2024
MedLife achieved a Pro forma consolidated turnover of RON 2.76 billion in 2024, up 25% compared to 2023, moreover, recording in the last five years increases in turnover of over 20%. - Despite the growth and consolidation of its leading…
- MedLife achieved a Pro forma consolidated turnover of RON 2.76 billion in 2024, up 25% compared to 2023, moreover, recording in the last five years increases in turnover of over 20%.
- Despite the growth and consolidation of its leading position, the company navigated cautiously last year, taking into account the increase in debt and the decrease in profit registered at the end of 2023. At the same time, it managed to reduce its debt and gradually regain its margins.
- Even though it slowed down the pace of acquisitions (five last year), the Group accelerated strongly in the area of organic projects and opened no less than three new hospital units, probably becoming the largest provider of hospital services both in Bucharest and nationally.
- MedLife also recorded in 2024 several notable achievements in the field of cutting-edge medicine, one of which was the integration of AI into its application for interpreting laboratory results. The company also became a national leader in genetics and molecular biology, as well as precision imaging with its 40 MRIs, 30 CTs and 80 other equipment such as X-rays, mammograms or osteodensitometers, distributed nationwide. In fact, these will soon be included in the first imaging research program of a private Romanian company.
MedLife (BVB: M), the largest private healthcare network in Romania and the only company with domestic capital among the top private healthcare operators, announces its preliminary financial results for 2024, highlighting a significant increase in Pro forma consolidated turnover, which reached over RON 2.7 billion (EUR 555 million), up 25% compared to 2023. Thus, the Group becomes the first Romanian company in the private healthcare sector to exceed half a billion euros in turnover in 2024.
Also, Pro-forma EBITDA reached RON 412 million in 2024 compared to RON 317 million in the previous year, which highlights the Group's stability in terms of profitability growth in 2024. At the same time, the Pro-forma net profit obtained by the Group in 2024 amounted to RON 33 million.
“Despite a much slower economic growth of only 0.9%, the 2024 results attest that MedLife has managed to maintain its financial and operational business performance. Thanks to these results, which give us reasons for optimism, we will continue our development projects. In this regard, we have proposed to supplement the syndicated loan with 50 million euros and we hope to have it approved by shareholders in March. Although we expect a complicated year, marked by many geopolitical challenges and the need for significant fiscal adjustments in Romania, we have taken the necessary strategic measures to perform even in a period marked by uncertainties.
